Intellia Therapeutics’ (NTLA) Buy Rating Reaffirmed at Canaccord Genuity Group
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Canaccord Genuity Group in a research note issued on Tuesday,Benzinga reports. They presently have a $90.00 price target on the stock. A number of other research analysts have also recently commented on NTLA. The Goldman Sachs Group reduced […]
More Stories
News from the WHO: WHO Investment Round: culminating moment at G20 Summit as leaders pledge https://ift.tt/dekQnFb November 19, 2024 at 07:00AM
Published on November 19, 2024 at 07:00AM View on website
Insider Selling: Meta Platforms, Inc. (NASDAQ:META) COO Sells 620 Shares of Stock
Meta Platforms, Inc. (NASDAQ:META – Get Free Report) COO Javier Olivan sold 620 shares of the firm’s stock in a...
Nature’s Miracle (NASDAQ:NMHI) Shares Scheduled to Reverse Split on Thursday, November 21st
Nature’s Miracle Holding Inc. (NASDAQ:NMHI – Free Report) shares are set to reverse split before the market opens on Thursday,...
Travis Perkins (OTCMKTS:TVPKF) Sets New 12-Month Low – Here’s Why
Travis Perkins plc (OTCMKTS:TVPKF – Get Free Report)’s stock price reached a new 52-week low on Tuesday . The stock...
Varex Imaging (NASDAQ:VREX) Updates Q1 2025 Earnings Guidance
Varex Imaging (NASDAQ:VREX – Get Free Report) issued an update on its first quarter 2025 earnings guidance on Tuesday morning....
Datadog, Inc. (NASDAQ:DDOG) President Amit Agarwal Sells 150,000 Shares
Datadog, Inc. (NASDAQ:DDOG – Get Free Report) President Amit Agarwal sold 150,000 shares of the business’s stock in a transaction...